Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2701)	10/17/2003 12:49:00 PM
From: Jim Oravetz	Respond to of 7143

No FRX thread: FDA Approves Memantine For Treating Alzheimer's WASHINGTON -- The government on Friday approved a new option for sufferers of Alzheimer's disease, the first treatment specifically for late stages of the mind-robbing illness. Called memantine, the drug has long been sold in Germany and many U.S. families out of options try to buy supplies overseas via the Internet. Now armed with Food and Drug Administration approval, U.S. marketer Forest Laboratories Inc. will sell memantine here under the brand name Namenda, for patients with moderate to severe Alzheimer's symptoms. Forest said the drug should be on pharmacy shelves in January. CHECKUP ++++++++++++++ Memantine from Forest Laboratories Inc. Phenserine from Axonyx Inc. Huperzine-A from Savient Pharmaceuticals Inc. See drugs in development for the treatment of Alzheimer's disease. ++++++++++++++ Memantine doesn't offer miraculous benefits. The FDA's scientific advisers, in evaluating the drug last month, worried that memantine's debut could give false hope to families of the most severely ill. In studies, some patients given memantine have experienced improvements in memory and thinking skills. But for the vast majority the drug instead slows the pace of deterioration, letting patients maintain certain functions a little longer. For example, the drug helped some patients maintain the ability to go to the bathroom independently for six more months, a benefit caregivers called very important. It is an important step because memantine is the first option for advanced stages of Alzheimer's. The nation's four other Alzheimer's medications -- Aricept, Exelon, Reminyl and Cognex -- work in early stages of the disease. Those drugs work very differently from memantine. They delay the breakdown of a brain chemical called acetylcholine that is vital for nerve cells to communicate. Memantine, in contrast, blocks excess amounts of another brain chemical, called glutamate, that can damage or kill nerve cells. That means for the first time, doctors could prescribe combinations of drugs in hopes of better results. About four million Americans have Alzheimer's, and a million of them are believed to suffer severe symptoms.